JP2013199483A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013199483A5 JP2013199483A5 JP2013109643A JP2013109643A JP2013199483A5 JP 2013199483 A5 JP2013199483 A5 JP 2013199483A5 JP 2013109643 A JP2013109643 A JP 2013109643A JP 2013109643 A JP2013109643 A JP 2013109643A JP 2013199483 A5 JP2013199483 A5 JP 2013199483A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- unsubstituted
- substituted
- group
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 201000011510 cancer Diseases 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 208000029742 colonic neoplasm Diseases 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 6
- 206010017758 gastric cancer Diseases 0.000 claims 6
- 201000010536 head and neck cancer Diseases 0.000 claims 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 208000032839 leukemia Diseases 0.000 claims 6
- 201000007270 liver cancer Diseases 0.000 claims 6
- 208000014018 liver neoplasm Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 201000000849 skin cancer Diseases 0.000 claims 6
- 201000011549 stomach cancer Diseases 0.000 claims 6
- 201000002510 thyroid cancer Diseases 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 4
- 206010005949 Bone cancer Diseases 0.000 claims 4
- 208000018084 Bone neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- -1 geometric isomers Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010038038 rectal cancer Diseases 0.000 claims 4
- 201000001275 rectum cancer Diseases 0.000 claims 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims 2
- 201000009047 Chordoma Diseases 0.000 claims 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010023774 Large cell lung cancer Diseases 0.000 claims 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000007641 Pinealoma Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 210000004100 adrenal gland Anatomy 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 230000009033 hematopoietic malignancy Effects 0.000 claims 2
- 208000006359 hepatoblastoma Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 210000003630 histaminocyte Anatomy 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 2
- 206010024627 liposarcoma Diseases 0.000 claims 2
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 208000001611 myxosarcoma Diseases 0.000 claims 2
- 208000025189 neoplasm of testis Diseases 0.000 claims 2
- 201000008026 nephroblastoma Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 208000024724 pineal body neoplasm Diseases 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000002926 oxygen Chemical group 0.000 claims 1
- 201000011098 spinal cord lymphoma Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74287505P | 2005-12-07 | 2005-12-07 | |
| US60/742,875 | 2005-12-07 | ||
| US77256706P | 2006-02-13 | 2006-02-13 | |
| US60/772,567 | 2006-02-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544002A Division JP5464856B2 (ja) | 2005-12-07 | 2006-12-07 | ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013199483A JP2013199483A (ja) | 2013-10-03 |
| JP2013199483A5 true JP2013199483A5 (enExample) | 2014-02-13 |
Family
ID=38038558
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544002A Active JP5464856B2 (ja) | 2005-12-07 | 2006-12-07 | ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法 |
| JP2013109643A Pending JP2013199483A (ja) | 2005-12-07 | 2013-05-24 | ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008544002A Active JP5464856B2 (ja) | 2005-12-07 | 2006-12-07 | ジャスモネートの化学的誘導体、医薬組成物及びこれらの使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090291904A1 (enExample) |
| EP (3) | EP2402321A3 (enExample) |
| JP (2) | JP5464856B2 (enExample) |
| AU (1) | AU2006322844A1 (enExample) |
| BR (1) | BRPI0619492A2 (enExample) |
| CA (1) | CA2632653C (enExample) |
| DK (1) | DK2617714T3 (enExample) |
| ES (1) | ES2576980T3 (enExample) |
| WO (1) | WO2007066336A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9284274B2 (en) * | 2005-12-07 | 2016-03-15 | Ramot At Tel-Aviv University Ltd. | Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof |
| AU2006322844A1 (en) * | 2005-12-07 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof |
| CN101511351A (zh) * | 2006-07-10 | 2009-08-19 | 雷蒙特亚特特拉维夫大学有限公司 | 治疗癌症的组合方法 |
| WO2008111088A2 (en) | 2007-03-15 | 2008-09-18 | Ramot At Tel-Aviv University Ltd. | Jasmonate based assays for identifying compounds that selectively inhibit mitochondrial bound hexokinases |
| US9284252B2 (en) | 2009-06-09 | 2016-03-15 | Sepal Pharma Ltd. | Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders |
| WO2012079058A2 (en) * | 2010-12-10 | 2012-06-14 | Broady Health Sciences, Llc | Use of jasmonate to treat bladder dysfunction |
| RU2014114931A (ru) | 2011-09-16 | 2015-10-27 | Нанокэа Текнолоджиз, Инк. | Композиции соединений жасмонатов и способы применения |
| JP6081873B2 (ja) * | 2013-06-24 | 2017-02-15 | 旭化成ファインケム株式会社 | 界面活性剤 |
| KR20170125811A (ko) | 2014-12-31 | 2017-11-15 | 나노케어 테크놀로지스 인코퍼레이티드 | 자스모네이트 유도체 및 그 조성물 |
| EP3435990B1 (en) * | 2016-03-28 | 2021-01-27 | VIDAC Pharma Ltd. | Stable pharmaceutical compositions for topical administration and uses thereof |
| AU2017311691B2 (en) | 2016-08-18 | 2021-12-02 | Vidac Pharma Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
| EP4464334A3 (en) | 2016-11-07 | 2025-01-08 | VIDAC Pharma Ltd. | Use of compounds for treating hk2-expressing cancers |
| WO2018083704A1 (en) | 2016-11-07 | 2018-05-11 | Vidac Pharma Ltd. | Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses |
| EP3735402A4 (en) * | 2018-01-07 | 2021-08-18 | VIDAC Pharma Ltd. | PROCESS FOR PRODUCING JASMONATE COMPOUNDS |
| CN113768911B (zh) * | 2021-10-20 | 2023-10-27 | 郑州大学 | Apobec3b抑制剂及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3981891A (en) * | 1972-01-18 | 1976-09-21 | Societe Anonyme Roure Bertrand Dupont | Cyclopentanone derivatives, odoriferous compositions containing them and process of preparation thereof |
| FR2168147B1 (enExample) * | 1972-01-18 | 1974-11-08 | Roure Bertrand Dupont Sa | |
| ZA747723B (en) * | 1974-12-11 | 1976-11-24 | Pfizer | 11-desoxy-15-substituted-omega-pentanor prostaglandins |
| US3932389A (en) * | 1974-12-11 | 1976-01-13 | Pfizer Inc. | 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins |
| US4154949A (en) * | 1974-12-11 | 1979-05-15 | Pfizer Inc. | 11-Desoxy-15-substituted-ω-pentanor prostaglandins |
| JPH06122653A (ja) * | 1992-08-25 | 1994-05-06 | Japan Tobacco Inc | 飽和単環炭化水素化合物の製造方法およびその中間体 |
| US5476945A (en) * | 1992-11-17 | 1995-12-19 | Fuji Photo Film Co., Ltd. | Water-soluble methine derivatives of thiazole |
| EP1348764A1 (en) * | 1993-11-15 | 2003-10-01 | Mitsui Chemicals, Inc. | A Method of Producing a Taxane-Type Diterpene and Method of Obtaining Cultured Cells which Produce the Taxane-Type Diterpene at a High Rate |
| JP4041186B2 (ja) * | 1997-07-09 | 2008-01-30 | 独立行政法人科学技術振興機構 | ファイトアレキシン誘導剤 |
| JPH11140022A (ja) * | 1997-11-12 | 1999-05-25 | Nippon Zeon Co Ltd | ジャスモン酸系化合物とその製法 |
| JPH11139908A (ja) * | 1997-11-12 | 1999-05-25 | Nippon Zeon Co Ltd | ジャスモン酸系化合物を含有する寄生植物用発芽誘導剤 |
| JP3815919B2 (ja) * | 1999-05-26 | 2006-08-30 | 三井化学株式会社 | タキサン型ジテルペンの製造方法 |
| US20030219461A1 (en) * | 2000-09-12 | 2003-11-27 | Britten Nancy J. | Parenteral combination therapy for infective conditions |
| US6861431B2 (en) * | 2001-03-23 | 2005-03-01 | The Board Of Trustees Of The University Of Illinois | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same |
| US6469061B1 (en) * | 2001-04-04 | 2002-10-22 | Ramot University Authority For Applied Research And Industrial Development Limited | Jasmonate pharmaceutical composition for treatment of cancer |
| FR2825926A1 (fr) * | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
| FR2835526B1 (fr) * | 2002-02-04 | 2006-02-10 | Oreal | Nouveaux composes, compositions les comprenant et leur utilisation pour favoriser la desquamation |
| FR2835525B1 (fr) * | 2002-02-04 | 2006-02-10 | Oreal | Nouveaux composes, compositions les comprenant et leur utilisation pour favoriser la desquamation |
| US20030224024A1 (en) * | 2002-02-04 | 2003-12-04 | Jean-Luc Leveque | Compositions comprising cyclopentane derivatives and their use |
| US7460960B2 (en) * | 2002-05-10 | 2008-12-02 | Epitome Biosystems, Inc. | Proteome epitope tags and methods of use thereof in protein modification analysis |
| FR2843125B1 (fr) * | 2002-08-02 | 2012-11-16 | Coletica | Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs |
| WO2004091516A2 (en) * | 2003-04-10 | 2004-10-28 | Johns Hopkins University | Methods for controlling the proliferation of cells |
| CN1193979C (zh) * | 2003-06-23 | 2005-03-23 | 华东理工大学 | 茉莉酮酸酯衍生物及其在植物细胞中的应用 |
| EP1689696A2 (en) * | 2003-12-02 | 2006-08-16 | Ramot at Tel-Aviv University Ltd. | Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof |
| US7026279B2 (en) * | 2004-06-24 | 2006-04-11 | International Flavors & Fragrances Inc. | Use of 3-(methoxymethyl)-2-pentylcyclopenta derivatives in perfume compositions |
| AU2006322844A1 (en) * | 2005-12-07 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof |
-
2006
- 2006-12-07 AU AU2006322844A patent/AU2006322844A1/en not_active Abandoned
- 2006-12-07 US US12/095,908 patent/US20090291904A1/en not_active Abandoned
- 2006-12-07 WO PCT/IL2006/001408 patent/WO2007066336A2/en not_active Ceased
- 2006-12-07 BR BRPI0619492-3A patent/BRPI0619492A2/pt not_active IP Right Cessation
- 2006-12-07 EP EP11171983A patent/EP2402321A3/en not_active Withdrawn
- 2006-12-07 JP JP2008544002A patent/JP5464856B2/ja active Active
- 2006-12-07 EP EP13159825.2A patent/EP2617714B1/en active Active
- 2006-12-07 CA CA2632653A patent/CA2632653C/en active Active
- 2006-12-07 DK DK13159825.2T patent/DK2617714T3/da active
- 2006-12-07 ES ES13159825.2T patent/ES2576980T3/es active Active
- 2006-12-07 EP EP06821626A patent/EP1960364A2/en not_active Withdrawn
-
2013
- 2013-05-24 JP JP2013109643A patent/JP2013199483A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013199483A5 (enExample) | ||
| JP5881705B2 (ja) | Ｎａｍｐｔの阻害のための新規化合物及び組成物 | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| FI3810602T3 (fi) | Yhdisteitä | |
| WO2016161361A4 (en) | Compositions and methods of targeting mutant k-ras | |
| RU2017105781A (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
| JP2009519907A5 (enExample) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2016513660A5 (enExample) | ||
| JP2014530811A5 (enExample) | ||
| JP2008528467A5 (enExample) | ||
| JP2018504378A5 (enExample) | ||
| RU2012141590A (ru) | Соединения для лечения рака | |
| JP2013535491A5 (enExample) | ||
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| JP2015520753A5 (enExample) | ||
| JP2011511095A5 (enExample) | ||
| JP2017525730A5 (enExample) | ||
| JP2009534408A5 (enExample) | ||
| NZ628078A (en) | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
| JP2013521281A5 (enExample) | ||
| JP2012153722A5 (enExample) | ||
| RU2011150250A (ru) | Антагонисты пути hedgehog и их терапевтическое применение | |
| RU2013109143A (ru) | Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы | |
| JP2013538213A5 (enExample) |